TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas
Phase 1
Recruiting
- Conditions
- Brain TumorBrain MetastasesBrain CancerGliomaGliomas, MalignantGlioblastomaMeningioma
- Interventions
- Biological: Tumor Infiltrating Lymphocytes (TIL)
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Essen Biotech
- Target Recruit Count
- 85
- Registration Number
- NCT06640582
- Locations
- 🇨🇳
District One Hospital, Beijing, Beijing, China
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
Phase 1
Recruiting
- Conditions
- Lung Cancer, Non-small CellLung Cancer RecurrentLung CancerLung Cancer Metastatic
- Interventions
- Biological: Tumor Infiltrating Lymphocytes (TIL)
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Essen Biotech
- Target Recruit Count
- 85
- Registration Number
- NCT06538012
- Locations
- 🇨🇳
District One Hospital, Beijing, Beijing, China
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer
Phase 1
Recruiting
- Conditions
- Stomach CancerStomach Cancer RecurrentStomach Cancer, AdenocarcinomaEsophageal CancerEsophageal Cancer Metastatic to BoneEsophageal Cancer Metastatic to LungEsophageal Cancer Metastatic to Liver
- Interventions
- Biological: Tumor Infiltrating Lymphocytes (TIL)
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Essen Biotech
- Target Recruit Count
- 75
- Registration Number
- NCT06532799
- Locations
- 🇨🇳
District One Hospital, Beijing, Beijing, China
TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer
Phase 1
Recruiting
- Conditions
- Breast CancerBreast CarcinomaBreast Cancer Triple NegativeBreast Cancer Metastatic
- Interventions
- Biological: Tumor Infiltrating Lymphocytes (TIL)
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Essen Biotech
- Target Recruit Count
- 85
- Registration Number
- NCT06532812
- Locations
- 🇨🇳
District One Hospital, Beijing, Beijing, China
Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer
Phase 1
Recruiting
- Conditions
- Colorectal CancerColon CancerRectum Cancer
- Interventions
- Biological: Tumor Infiltrating Lymphocytes (TIL)
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Essen Biotech
- Target Recruit Count
- 85
- Registration Number
- NCT06530303
- Locations
- 🇨🇳
District One Hospital, Beijing, Beijing, China
Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases
Phase 1
Recruiting
- Conditions
- Autoimmune DiseasesSystemic Lupus ErythematosusSystemic Lupus Erythematosus AcuteSjogren's Syndrome
- Interventions
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Essen Biotech
- Target Recruit Count
- 60
- Registration Number
- NCT06428188
- Locations
- 🇨🇳
District One Hospital, Beijing, Beijing, China
Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells
Phase 1
Recruiting
- Conditions
- T Cell LeukemiaT-cell Acute Lymphoblastic LeukemiaT-Cell Lymphoma of CNST Cell LymphomaT Cell Prolymphocytic LeukemiaT Cell Childhood ALL
- Interventions
- Biological: CD5/CD7 CAR-T
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Essen Biotech
- Target Recruit Count
- 60
- Registration Number
- NCT06420076
- Locations
- 🇨🇳
District One Hospital, Beijing, Beijing, China
Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML
Phase 1
Recruiting
- Conditions
- Acute Myeloid LeukemiaAMLAML, AdultAML, Adult Recurrent
- Interventions
- Biological: CD123/CD33 CART
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Essen Biotech
- Target Recruit Count
- 85
- Registration Number
- NCT06420063
- Locations
- 🇨🇳
District One Hospital, Beijing, Beijing, China
Investigation Into the Use of BAH243 Lentiviral Vector for Gene Therapy in Treating Sickle Cell Disease
Phase 1
Recruiting
- Conditions
- Sickle-Cell Disease With CrisisSickle Cell Disease
- Interventions
- Genetic: Drug Product is administered by IV infusion following myeloablative conditioning with busulfan
- First Posted Date
- 2024-05-03
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Essen Biotech
- Target Recruit Count
- 85
- Registration Number
- NCT06399107
- Locations
- 🇨🇳
District One Hospital, Beijing, Beijing, China
Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
Phase 1
Recruiting
- Conditions
- Microscopic PolyangiitisSjogren's SyndromeLupus NephritisSystemic Lupus ErythematosusSystemic SclerosisAutoimmune DiseasesAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisGranulomatous PolyangiitisIdiopathic Inflammatory Myopathies
- Interventions
- Biological: CD19- BCMA CAR-T cells
- First Posted Date
- 2024-04-05
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Essen Biotech
- Target Recruit Count
- 75
- Registration Number
- NCT06350110
- Locations
- 🇨🇳
District One Hospital, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath